Penn Engineers have redesigned a key component of lipid nanoparticles (LNPs), the delivery vehicles behind mRNA vaccines, to ...

- Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with Mitigated dsRNA and Reduced Turnaround Times - STONY BROOK, NY and ...

Many RNA programs are under increasing pressure to compress development timelines while ensuring consistent RNA quality and ...

Researchers have developed a new lipid nanoparticle design that directs mRNA to the pancreas by exploiting the organ’s own ...

Wacker Biotech, a CDMO, began a strategic collaboration with Boston-based RNAV8 Bio aimed at progressing the development and production of mRNA-based advanced therapies for the biopharma industry.

As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.

Experts deliberate on navigating the future of biologics & mRNA at the Indian Pharmaceutical Alliance webinar: Our Bureau, Bengaluru Monday, March 30, 2026, 16:45 Hrs [IST] Biolog ...

Sunshine Biopharma Inc. (NASDAQ:SBFM) traded higher on Wednesday, with a session volume of 19.07 million compared to an average volume of 88.16K, according to data from Benzinga Pro. The company on ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how an innovative and stable mRNA-LNP microneedle vaccine elicits humoral and multifunctional cellular immune responses. During ...